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Abstract: Diabetic vascular dysfunction is a major complication of diabetes. Methylglyoxal (MGO) is 
a dicarbonyl metabolite elevated in diabetic plasma that reacts with interstitial molecules to form 
advanced glycation end products (AGE). We investigated whether MGO affects the release of nitric 
oxide (NO) from rat aortic smooth muscle cells (ASMCs), and if L-arginine can prevent these effects 
of MGO. MGO was significantly elevated in serum from streptozotocin (STZ)-treated rats (121 ± 11.2 
µM) compared with vehicle control rats (27.5 ± 9.2 µM). The pathological concentration of MGO (100 
µM) was then applied to investigate its effect on inducible nitric oxide synthase (iNOS) expression 
and NO release on interferon-gamma (IFN-γ) (100 IU/ml) and lipopolysaccharide (LPS) (100 µg/ml)-
stimulated control ASMCs. MGO (100 µM) inhibited IFN-γ and LPS-stimulated iNOS expression 
through inhibiting Akt phosphorylation and inhibition of iNOS expression was prevented by L-
arginine (100 µM) co-treatment. These findings show for the first time that MGO inhibits IFN-γ and 
LPS-stimulated iNOS expression in ASMCs, in addition to inhibiting IFN-γ and LPS-induced Akt 
phosphorylation. The actions of MGO  might  contribute to the vascular dysfunction induced by 
MGO in diabetes. 
Keywords: Methylglyoxal; Diabetes mellitus; Nitric oxide; iNOS; vascular dysfunction; L-
arginine 
1. Introduction 
Vascular dysfunction is a major complication of diabetes where vasodilation is compromised 
rendering the diabetics prone to hypertension and microvascular dysfunction-induced organ damage 
such as nephropathy and myocardial infarction (American Diabetes Association, 2012). As a 
consequence of chronic hyperglycemia where blood glucose concentration exceeds 7 mmol/l (125 
mg/dl) (Sheader et al., 2001), approximately 0.5% of glycolysis generates reactive carbonyl species 
such as methylglyoxal (MGO) that is a precursor for reactive oxygen species (ROS). MGO reacts with 
various cellular and interstitial molecules such as proteins and phospholipids to form stable adducts 
and advanced glycation end products (AGE) (Uchida, 2000). Upon forming AGE, MGO is trapped 
intracellularly and subsequently increases the oxidative stress (OS). The resulting disruption of cell 
membrane integrity allows MGO leakage to the serum from where it can be measured for the 
assessment of disease progression and severity (Kalapos, 2013; Sheader et al., 2001). 
  Nitric oxide (NO) is a potent vasodilator that is generated by NO synthase (NOS), which 
oxidizes the substrate L-arginine into L-citrulline (Lin et al., 2003). NOS exists in three major isoforms, 
endothelial NOS (eNOS), inducible NOS (iNOS) and neuronal NOS (nNOS). A considerable body of 
work has suggested that endothelial dysfunction in diabetes and other chronic vascular pathologies 
includes reduced NO production through eNOS dysfunction in endothelial cells (Vanhoutte et al., 
2016). Much less studied is the calcium-independent NOS isoform, iNOS that is expressed 
predominantly in vascular smooth muscle cells, mediating vasodilation and contributes to 
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inflammatory responses (Kleinert et al., 2004). Vascular smooth muscle cells’ iNOS-derived NO is an 
important mechanism of vascular relaxation induced by drugs such as the oestrogen receptor 
modulator raloxifene (Wong et al., 2017). The contribution of this source of NO in disease states such 
as diabetes is less clear with some reports showing an increase in iNOS expression and NO release 
from vascular smooth muscle cells (Di Pietro et al., 2013; Nagareddy et al., 2005). Lipopolysaccharide 
(LPS), the bacterial endotoxin, evokes strong inflammatory responses and has been used as a tool for 
induction of iNOS. LPS-induced iNOS releases NO that reduces the noradrenaline (NA)-induced 
vasoconstriction, by activating calcium activated potassium channels (Kca channels) (Hall et al., 1996). 
Moreover, other studies have shown iNOS expression, following LPS infusion in vivo, reduces NA-
induced vasoconstriction through activation of the cGMP pathway (Gray et al., 1991; Wu et al., 1994), 
and tension changes are dependent on extracellular L-arginine (Schott et al., 1993).  
In this study, we show  in streptozotocin (STZ) diabetic rats, that NA-induced vasoconstriction 
increases alongside increases in serum levels of MGO.  We then investigate the hypothesis that this 
enhanced exaggerated vasoconstriction might be due to a reduction in NO-mediated relaxation 
resulting from changes in iNOS expression. In aortic smooth muscles cells (ASMCs) cultured from 
STZ-treated rats, iNOS expression and iNOS-induced NO release were compared to ASMCs from 
control rats. We next investigated the direct effects of MGO on iNOS expression and iNOS-induced 
NO from control ASMCs to see if MGO could inhibit iNOS function, and whether the NOS substrate 
and MGO scavenger, L-arginine is able to reverse these MGO effects. 
2. Materials and Methods 
2.1. Reagents 
Bicinchoninic acid (BCA) assay reagents, protein assay reagent A (11881345) and protein assay 
reagent B (10475944), and cell culturing reagents, Dulbecco’s Modified Eagle Medium (DMEM) 
(10135082), newborn bovine calf serum (10014173), antibiotic/antimycotic solution (100x) (10101043), 
trypsin 2.5% (10217723), Hanks’ Balanced Salt Solution (HBSS) (10X) (10227632) were purchased from 
Fisher-Scientific (Loughborough, UK). Membrane filter Immobilon-P transfer membranes 0.45 µm 
pore size (IPVH00010) were all purchased from Fisher-Scientific (Loughborough, UK). Streptozotocin 
(S0130), L- noradrenaline (A7257), L-arginine (A5006), methylglyoxal (M0252), lipopolysaccharides 
from Escherichia coli 0111:B4 (100MG) (L2630), luminol (A8511), p-coumaric acid (C9008), goat anti-
rabbit IgG (whole molecule)–peroxidase antibody (a6154) produced in goat and mouse monoclonal 
anti-β-actin−peroxidase antibody (A3854) were all purchased from Sigma Aldrich (Gillingham, UK). 
Interferon- γ, rat, recombinant, E. coli (407321) was purchased from Merck chemicals (Nottingham, 
UK). Biotinylated protein ladder detection pack (7727S) was purchased from New England biolabs 
(Hitchin, UK). Rabbit anti-iNOS antibody (200 µl) (ab3523) was purchased from Abcam (Cambridge, 
UK). Anti phospho-Akt (9271) and anti MAPK p38 (9211) were purchased from Cell Signalling UK. 
2.2. STZ-diabetes modelling 
All rats were kept under standard housing conditions with freely available food and water at 
controlled temperature 20 ± 2°, humidity at 55 ± 10% and 12 h day-night cycle, all studies were 
approved by the Institutional Animal Welfare and Ethics review committee and conducted in 
accordance with guidelines established by the Animals (Scientific Procedures) Act 1986 and European 
directive 2010/63/EU carried out under project license PPL70/7732. For STZ-diabetes induction, male 
Wistar rats (350-450 g) (Charles River, UK) were housed in pairs and given a single injection of 65 
mg/kg streptozotocin (STZ; dissolved in 20 mM citrate buffer pH 4.5) intraperitoneally (i.p., DV 10 
ml/kg) (De la Garza-Rodea et al., 2010). For 48 h following STZ or control injection (20 mM citrate 
buffer) an additional choice of 2% sucrose solution was provided, to avoid the initial hypoglycemia 
that is seen following STZ administration. For all control and STZ-injected rats, food was also 
changed from 14% protein (LabDiet 5LF2, EURodent Diet 14%) into protein rich diet 22% protein 
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(LabDiet 5LF5, EURodent Diet 14%) after injection to compensate possible diabetes-induced protein 
loss. 
Body weight was monitored every day for a minimum of 2 weeks post injection, and diabetes was 
confirmed by testing a drop of tail vein blood (Accu-check blood glucose monitor); rats showing an 
elevated blood glucose > 16 mmol/l were considered diabetic. Blood glucose levels were measured at 
three-time periods; (i) Prior to STZ or vehicle injection, (ii) 2-7 days post injection, and (iii) Prior to 
euthanizing (week 1 to week 5). 
2.3. Serum MGO measurement 
Serum samples were analyzed through sandwich ELISA according to the manufacturer’s instructions 
(Cell Biolabs, STA-811). Briefly, a sterile 96 well plate was coated with 100 µl of 50 ng/ml MGO 
conjugate which was prepared by the supplier through reacting bovine serum albumin (BSA) with 
MGO, followed by extensive dialysis and column purification. Serum samples (50 µl) were incubated 
at 25° for 10 min prior to the addition of primary monoclonal mouse anti-MGO antibody (50 µl); 
samples were incubated at room temperature on an orbital shaker for 1 hour. All samples were 
washed with washing buffer before the addition of 100 µl secondary horseradish labelled goat anti-
mouse antibody for 1 hour on an orbital shaker. Wells were washed three times and then incubated 
with 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate solution (100 µl) for 5 min; the reaction was 
stopped using 100 µl sulphuric acid stop solution and absorbance measured at 450 nm. 
2.4. Aortic rings contraction studies: 
To examine the extent of vasoconstriction in STZ-diabetic rats and vehicle control rats, as previously 
mentioned (Shamsaldeen et al., 2018), rats were euthanized through schedule 1 procedures that 
includes CO2 asphyxiation and spinal dislocation. Thereafter, thoracic aorta was freshly dissected and 
plunged into oxygenated Krebs solution and cut into 1-2 mm rings. Then, the aortic rings were  hung 
in a Bennett isolated tissue organ bath filled with Krebs solution pH 7.4 at 37°C ± 1°C and gassed with 
95% O2/5% CO2. Aortic rings were equilibrated for 60 min before conducting any experiment. Aortic 
ring’s response was measured through FT-100 force transducer and iWORKS amplifier that generates 
electrical signals recorded through Labscribe software from iWORKS (version 1.817). Aortic rings 
were treated with freshly prepared EC80 (300 nM) concentration of NA, and tension was measured. 
The increase in tension was measured above baseline value (1g) before adding the vasoconstrictor. 
 
2.5. Primary aortic smooth muscle cells studies 
Primary rats’ ASMCs were extracted through explants. Briefly, thoracic aorta was isolated from 
vehicle and STZ-treated rats and plunged into complete Dulbecco’s Modified Eagle Medium (DMEM) 
with L-glutamine 1000 mg/l, D-glucose, sodium pyruvate, 25 mM HEPES supplemented with 15% 
new born calf serum and streptomycin (100 µg) penicillin (100 units). The aorta was mechanically 
stripped from the adventitia and cut into small rings, and endothelium removed using autoclaved 
forceps. The flask was added with 3ml complete media and placed vertically in the incubator to allow 
the adherence of the explants for 90 min. The flask is then placed horizontally so the explants are 
supplemented with media. Cell growth was checked daily and half of the media was changed after 4 
days (Kenagy et al., 1997). The cells were grown to reach approximately 100% confluence before being 
trypsinized and transferred into T-75 flasks where they were grown to reach approximately 100% 
confluence. Once confluent, the cells were plated into 12 well plates in approximately 300000 
cell/ml/well. The next day, cells were refreshed with new complete media and after 48 h from plating, 
the ASMCs were confluent and used for experiments. Western blots were analyzed through ImageJ 
1.46r, and each protein band was analyzed through densitometric analysis by being normalized to its 
correspondent β-actin. Afterward, the densitometric results were normalized to the densitometric 
result of the IFN + LPS positive control as %. 
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2.6. Total nitrite (NO2) measurement 
Confluent ASMCs were washed three times with HBSS, before adding complete media with IFN-
γ (100 IU/ml) and LPS (100 µg/ml) together with different concentrations of MGO representing the 
physiological and pathological concentration (10 and 100 µM, respectively) as well as without MGO 
(positive control) in addition to untreated cells (negative control). The cells were then incubated at 37° 
CO2 5% for 24 h. Nitric oxide (NO) was estimated indirectly through total nitrite (NO2) measurement. 
The reaction based on oxidizing all produced NO into NO2 from 100 µl of the well media which was 
then added with 100 µl Griess mixed reagents A and B (1:1 Griess reagents ratio), Sulfanilamide and 
N-1-naphthylethylenediamine, respectively. The reaction generates pink azo dye proportional to the 
total NO2 concentration. The samples were then read at 540 nm with an automated spectrophotometer 
(Coneski and Schoenfisch, 2012). Afterward, the total NO2 release was normalized to the total NO2 
released from ASMCs treated with LPS and IFN-γ only (positive control), with the NO2 released in 
the positive control normalized as 100%. 
 
2.7. Statistical analysis 
Data were analyzed through GraphPad Prism (version 5). Data are expressed as mean ± S.E.M. 
and compared through one-way ANOVA post hoc Tukey’s test, two-way ANOVA post hoc 
Bonferroni’s test or unpaired Student t-test. The P-value was considered significant when less than 
0.05. 
 
3. Results 
3.1. Blood glucose was significantly elevated in STZ-diabetic rats 
Blood glucose was measured to confirm that the STZ-injected rats develop hyperglycemia. 95% of 
STZ-injected rats developed hyperglycemia characterized by blood glucose concentration ˃ 16 mmol/l 
from week 1 as shown in Fig. 2. Hyperglycemia was sustained over the 5 weeks period of study. 
3.2. Methylglyoxal was significantly increased in serum from STZ-treated rats associated with 
increased NA-induced vasoconstriction: 
ELISA assay of MGO showed a significant increase in serum MGO in STZ-treated rats; greater 
than 5-fold higher than vehicle control rat serum (18.7 ± 3.7 µM) from week 1 to week 5 (from 97.0 ± 
26.4 µM to 201.2 ± 44.4 µM) as shown in Fig. 3A. Diabetic vascular tissue is well known to show 
increased contractility and we next sought to establish the time course of this pathology in our model. 
Aortic rings were exposed to the EC80 concentration of 300 nM NA until tension plateaued. 
Significant increase in vascular contractility was observed in all STZ-diabetic rats’ aortic rings (Fig. 
3B). Moreover, it should be noted that the EC80 was similar in aortic rings from both STZ and vehicle 
control rats. 
3.3. iNOS expression was significantly suppressed in STZ-diabetic primary ASMCs 
As previously reported, LPS induces iNOS expression and therefore, NO release that causes 
vasodilation and hypo-reactivity to vasoconstrictors such as phenylephrine (Hall et al., 1996). So, we 
next investigated whether iNOS expression is also impaired in diabetes and what might contribute to 
such an effect. Confluent primary ASMCs were treated with a standard inflammatory cocktail,  
interferon-gamma (IFN-γ) (100 IU/ml) and lipopolysaccharide (LPS) (100 µg/ml) to induce iNOS 
(Uemura et al., 2002). The Griess assay and SDS-PAGE Western blotting were performed to assess 
total nitrite (NO2) production and iNOS protein levels respectively. 
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Total NO2 release and iNOS expression from primary ASMCs isolated from naïve and STZ-treated 
rats were compared. ASMCs isolated from STZ-treated rats incubated with IFN-γ and LPS (positive 
STZ) for 24 h showed significantly less increase in iNOS expression compared to control ASMCs (Fig. 
4C). Total NO2 release was also significantly reduced in STZ-diabetic ASMCs (Fig. 4D). 
3.4. MGO significantly suppressed iNOS expression and NO2 release in control ASMCs 
Since ASMCs from STZ-treated rats (2-3 week) with chronically elevated MGO levels showed 
significant reduction in total NO2 release and iNOS expression following IFN-γ and LPS induction 
(Fig. 4), we next looked at the effect of acute MGO treatment on total NO2 release and iNOS 
expression in naïve rat primary ASMCs. ASMCs were treated with IFN-γ and LPS to stimulate iNOS 
expression and NO2 production in the presence of MGO at physiological and pathological 
concentrations, 10 µM and 100 µM, respectively. Moreover, since a previous study showed MGO (100 
µM) inhibitory effect on eNOS activation when aortic rings were incubated with MGO for 2 h (Dhar 
et al., 2010), therefore, two different incubation periods were studied; 2 h and 24 h. Accordingly, 
when ASMCs were incubated with IFN-γ, LPS and 100 µM MGO for 24 h a significant reduction in 
iNOS expression and total NO2 release was seen, but not with 10 µM MGO. Incubating ASMCs with 
IFN-γ and LPS for 24 h and with 100 µM MGO for 2 h causes non-significant reduction to iNOS 
expression and total NO2 release (Fig. 5). 
These results suggest that the increased NA evoked tension seen after STZ treatment might be due to 
inhibition of iNOS expression.  We thus tested this in intact aorta with endothelium removed to 
mirror the ASMCs cultures. Endothelium denuded rings (produced by gentle rubbing with a cotton 
wool bud)were treated with L-NAME for 30 min to inhibit ASMCs NOS before  the 300 nM NA 
addition. In this experiment denuded rings treated with L-NAME showed significantly greater NA-
induced tension 0.47 ± 0.05 g compared to untreated controls 0.30 ± 0.02 g, P ˂ 0.01, consistent with 
the idea that there is resting NOS mediated NO release in ASMC in intact aorta rings. 
3.5. Methylglyoxal significantly inhibited Akt phosphorylation but not MAPK p-38 in control 
ASMCs 
Previous studies have shown that Akt phosphorylation is essential for IFN-γ/LPS-induced iNOS 
expression in vascular smooth muscle cells (VSMCs) (Hattori et al., 2003). Moreover, mitogen 
activated protein kinase (MAPK) p38 phosphorylation was shown to be involved in insulin-induced 
iNOS expression in VSMCs (Begum and Ragolia, 2000). We thus next looked at levels of phospho-Akt 
(Ser473) and phospho-p38 (Thr180/Tyr182) in our ASMCs cultures to investigate the mechanism 
through which iNOS was inhibited.  
ASMCs incubated with IFN-γ and LPS for 24 h showed a significant increase in phospho-Akt and this 
increase was blocked by incubation with IFN-γ, LPS and MGO 100 µM for 24 h (Fig. 6). 
However, when ASMCs were incubated with IFN-γ, LPS and MGO 100 µM for 24 h it did not show 
significant reduction in phosphorylated-p38, nor did IFN-γ and LPS treatment alone induce an 
increase in phosphorylated-p38 (Fig. 7).  
3.6. L-arginine treatment reversed MGO-induced iNOS inhibition 
L-arginine has been shown to reverse the effects of MGO on NO production in some systems and 
this has been suggested to be due to an MGO scavenging effect or to competition at the NOS substrate 
site (Dhar et al., 2010). So, it was of interest to investigate the effect of L-Arginine on the MGO-
inhibitory effect on iNOS expression. L-Arginine added to ASMCs in addition to IFN-γ, LPS and 
MGO reversed the inhibitory effect of MGO on IFN-γ and LPS-induced iNOS expression. L-Arginine 
did not significantly change the IFN-γ and LPS-induced increase in iNOS expression by itself nor did 
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it change levels of basal iNOS expression Fig. 8C. Similar effects of L-Arginine were seen on total NO2 
release. L-Arginine blocked the inhibition of total NO2 release by MGO without affecting IFN-γ and 
LPS-induced total NO2 release or basal levels of total NO2 release (Fig. 8D). Taken together this Data 
are consistent with the hypothesis that L-Arginine is acting as a scavenger of MGO preventing the 
inhibition of iNOS induction. 
4. Discussion 
Blood glucose concentration was used as a marker for diabetes as rats were considered diabetic 
when their blood glucose readings exceed 16 mmol/l. STZ was shown to induce hyperglycemia (4-
fold blood glucose increase) in 95% of the STZ-injected rats.  This study was conducted between week 
1-5 post-STZ injection which showed significant increase in blood glucose as shown in Fig. 2, these 
findings were similar to what was reported in a previous study (Bagri et al., 2009). This is essentially a 
model of type 1 diabetes. 
MGO was significantly increased in blood from STZ-treated rats by approximately 5-fold to about 
100 µM (Fig. 3A). This is similar to the MGO concentration (100 µM) applied by Dhar et al. (2010) to 
aortic rings to examine MGO-induced endothelial dysfunction. The elevation in serum MGO was 
accompanied by a 4-fold increase in blood glucose concentration, consistent with the idea that 
glycolysis is the main endogenous pathway for MGO generation (Sheader et al., 2001). MGO is 
generated during glycolysis by triose-phosphate enzymatic metabolism which was found to be 
increased in hyperglycemia (Kalapos, 2013; Thornalley et al., 2001). In addition to glycolysis, lipid 
catabolism (lipolysis) and protein catabolism (proteolysis) are also major endogenous MGO sources 
(Kalapos, 2013; Shamsaldeen et al., 2016). Lipolysis involves triose-phosphate generation through α-
glycerol-phosphate dehydrogenase-metabolized glycerol (Kalapos, 2013). Additionally, lipolysis is 
increased in diabetes and suppression of lipolysis improves insulin sensitivity and glucose utilization 
(Arner and Langin, 2014; Lim et al., 2011).  
In STZ-treated rats’ serum MGO levels and NA-induced vascoconstriction both increased 
significantly from week 1. From week 1-5 MGO levels varied around a level of 120 µM while NA-
induced vasoconstriction continued to slowly increase to approximately double control levels. This 
difference in timecourse might be due to complex pharmacodynamics resulting from MGO exposure, 
or it may mean that other factors also affect contractility. Mean MGO levels were variable and were 
not significantly above control at 4 weeks. Taken together with the other weekly MGO levels we 
attribute this lack of significance to the reduced power of N= 4  MGO samples at this timepoint. 
Aortic rings from STZ-diabetic rats showed significantly increased NA-induced vasoconstriction 
when compared with vehicle control aortic rings (Fig. 3B) without any change in EC80. This suggests 
that affinity of NA binding was not affected by MGO and that the MGO effect is due to downstream 
signaling changes increasing response efficacy. This is consistent with a reduction  in NO signaling. 
Our experiments with isolated ASMCs showed good association between, iNOS levels and total 
NO2 production, suggesting that iNOS is the major source of NO in these experiments.  Recent work 
by Wong et al. suggests that iNOS generated NO can induce significant vasodilation when stimulated 
by drugs such as raloxifene (Wong et al., 2017). In addition, iNOS-derived NO plays a preventive role 
against increased vasoconstriction responses in the inflammatory conditions  associated with 
arteriosclerosis (Fukumoto et al., 1997).  We have not excluded the possibility that nNOS contributes 
as there is some evidence that nNOS is expressed in some ASMCs although this varies in different 
strains (Boulanger et al., 1998). 
The significant reduction in iNOS expression from STZ ASMCs stimulated with IFN-γ and LPS 
(Fig. 4) differs from results of other studies.  Diabetic ASMCs when treated with LPS only, rather than 
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IFN-γ and LPS, showed iNOS upregulation (Di Pietro et al., 2013; Nagareddy et al., 2005). The 
differences may be due to inflammatory stimulus or perhaps more likely diabetic model and or time 
of study, as Di Pietro et al. used a partial pancreatectomy model and Nagareddy et al. looked mostly 
at a 12-week time point.  Overall levels of iNOS activity may be due to a combination of stimulatory 
effects of diabetes mediated inflammatory stimuli and inhibition due to factors such as MGO levels 
(next section). 
To the best of our knowledge this is the first study to examine the effect of MGO on iNOS 
expression on primary ASMCs treated with IFN-γ and LPS. IFN-γ and LPS are known iNOS-
inducers, and they are involved in immunogenic inflammatory response since IFN-γ is an 
inflammatory mediator, while LPS is a bacterial cell wall component (Kleinert et al., 2004). MGO was 
applied in both physiological (10 µM) and pathological concentrations seen in our diabetes model 
(100 µM) on primary ASMCs treated with IFN-γ and LPS. Treatment of ASMCs for 24 h (and not 2 h) 
with diabetic levels of MGO (100 µM) suppressed iNOS expression which was accompanied with 
greatly reduced NO release (Fig. 5). Thus, in addition to MGO being an eNOS inhibitor (Dhar et al., 
2010), MGO suppresses iNOS expression (Fig. 5).  
Akt and p38 phosphorylation were investigated as previous reports have showed the essential 
role of these two protein kinases in regulating iNOS expression (Begum and Ragolia, 2000; Hattori et 
al., 2003). As shown in Fig. 6, Akt phosphorylation was significantly reduced in ASMCs incubated 
with IFN-γ (100 IU/ml), LPS (100 µg/ml) and MGO (100 µM) over 24 h. A recent study has shown 
MGO (500 µM)-induced apoptosis of  endothelial cells through inhibiting Akt phosphorylation as 
well as suppressing other survival factors such as Bcl-2 protein (Chu et al., 2016). Another study has 
concluded that MGO (500 µM) prevented the insulin-dependent activation of the IRS1/protein kinase 
Akt/eNOS pathway, thus reducing NO production in mouse aortic endothelial cells (Nigro et al., 
2014).  P-Akt phosphorylates IκB, tagging it for ubiquitination and degradation. Once IκB is 
degraded, nuclear factor κB (NF- κB) becomes active and translocates into the nucleus to induce iNOS 
expression (Hattori et al., 2003). A recent study conducted where iNOS-induced vasodilation was 
significantly suppressed by NF- κB inhibitor pyrrolidine dithiocarbamate (3 µM) (Wong et al., 2017) is 
consistent with this mechanism. Lower concentrations of MGO may have different effects. Chang et 
al. (2011)  showed that 10 and 30µM MGO activates Akt in VSMC and promotes cell proliferation, 
while 10 µM MGO did not show any significant effect in our model on iNOS levels, so we did not 
directly test its effect on Akt. 
In contrast to Akt, p38 phosphorylation was not significantly affected by MGO treatment (Fig. 7). 
However, as p-38 MAPKs are rapidly activated within 0.5-3 h, a full time course study would be 
needed to exclude any effect of MGO on p-38 MAPKs in regulating iNOS expression  (Chan and 
Riches, 2001). These authors also showed that both ERK and JNK MAPKs are also involved in 
modulating the IFN-γ and LPS-stimulated iNOS (Chan and Riches, 2001). Also, human umbilical vein 
endothelial cells showed  MGO-induced concentration-dependent activation of JNK and p38 MAP 
kinase (Yamawaki et al., 2008) Therefore, it would be interesting to investigate the effect of MGO on 
these two MAPKs in addition to Akt and p-38.   
Taken together with Fig. 6 the data shows that MGO prevents IFN-γ + LPS-induced Akt 
phosphorylation and such an effect may contribute to increased vasospastic responses shown in Fig. 
3B since iNOS-derived NO plays a preventive role against increased vasospastic responses 
(Fukumoto et al., 1997). Moreover, since Akt plays a major role in glucose metabolism  in addition to 
being a cell survival factor (Franke et al., 1997), MGO elevation in diabetes might exacerbate the 
effects of hyperglycaemia (Dhar et al., 2011; Nicolay et al., 2006; Ramasamy et al., 2005). 
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A previous study revealed that 300 µM L-arginine serves as an MGO scavenger (Dhar et al., 
2012). Therefore, in this study L-arginine was applied to MGO-treated ASMC cultures which showed 
that L-arginine  restores  iNOS expression by LPS and IFN-γ in the presence of MGO (Fig. 8). As L-
arginine reverses the effect of MGO on iNOS expression, this suggests that adding exogenous L-
arginine is not merely providing further substrate for iNOS.  If this was the case, we might expect to 
see an increase in total NO2 production with no change in iNOS protein levels. L-arginine by itself is 
unable to significantly induce iNOS, and when added with LPS and IFN, it did not show significant 
induction when compared to the positive control of LPS and IFN alone (P ≥ 0.05), further supporting 
the idea that this is an MGO scavenging effect. In our study, L-arginine was applied as 100 µM which 
is close to the normal plasma concentration (60-140µM) (Schwedhelm et al., 2008). L-arginine 
supplementation will also help to prevent substrate limitation of NO production which can result in 
uncoupling of NOS and increased free radical generation. Our findings suggest that L-arginine 
supplementation may have therapeutic potential for diabetics. Previous studies revealed that L-
arginine supplementation (3x2 g/day) showed significant improvement in antioxidant levels and NO 
release (Jabłecka et al., 2012). Moreover, previous studies showed significant improvement in insulin 
sensitivity in patients with type 2 diabetes when they were given 8.3 g/day L-arginine. This 
improvement was accompanied by improved glucose metabolism and antioxidants capacity (Lucotti 
et al., 2006). A recent meta-analysis found some evidence of a reduction in infection rates (McRae, 
2016). These findings suggest further investigation of the clinical benefit of L-arginine as a 
supplement for diabetic patients is merited (Dhar et al., 2011; Eberhardt et al., 2012; Jia et al., 2006; 
Van Eupen et al., 2013). Further in vivo experiments on supplementing rats with L-arginine and 
measuring the vasocontractility response and iNOS-induced NO release in diabetic aortic rings would 
provide in vivo evidence for the role of L-arginine in reducing the exaggerated vasoconstriction. 
 
Conclusion 
MGO was elevated in serum from STZ-treated rats, iNOS expression and NO release was 
reduced, and vasoconstriction was exaggerated. These elevated levels of MGO and inhibited iNOS 
expression may contribute to diabetic complications such as compromised vasodilation and 
exaggerated vasoconstriction. Incubating control ASMCs with diabetic levels of MGO (100 µM) for 24 
h was associated with inhibiting Akt-phosphorylation and iNOS expression which might explain the 
increased vasoconstriction in aorta rings from STZ-treated rats. L-arginine (100 µM) treatment 
cancelled the MGO-inhibited, IFN-induced  iNOS expression. Therefore, further work will be needed 
to understand if these effects have any potential therapeutic benefit in treating MGO-related diabetic 
complications such as vascular dysfunction as a previous study revealed the ability of L-arginine to 
scavenge MGO   (Bierhaus et al., 2012; Dhar et al., 2010).  
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Fig. 1 Schematic diagram describing the methodology of the STZ-diabetic rat studies. iNOS: inducible nitric 
oxide synthase, MGO: methylglyoxal, NO2: total nitrite and STZ: streptozotocin. 
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Fig. 2 Blood glucose is elevated in streptozotocin (STZ) treated rats. Blood glucose concentration was measured 
pre- injection and on the day of sacrifice from week 1-5 post STZ-injection using an Accu-check Aviva (Roche) 
blood glucose meter. At weeks 1-5 the day of sacrifice values are compared with the pre-injection values for the 
same rats.  Data shown as mean ± S.E.M. (N= 5) and significance is represented as *** =P˂0.001 versus pre-
injection analyzed by paired two-tailed Student t-test. 
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Fig. 3 Serum methylglyoxal in streptozotocin (STZ)-injected rats is increased relative to vehicle control (A) 
and aortic ring contractility to noradrenaline (NA) (B). Data are presented as mean ± S.E.M. (A) serum 
methylglyoxal from vehicle control and STZ-diabetic rats from week 1 to week 5 (vehicle control, N= 4; week 1, 
N= 4; week 2, N= 5 ; week 3, N= 4; week 4, N= 4; week 5, N= 4. (B) Contractility of aortic rings from vehicle 
control and STZ-treated rats at weekly intervals post injection (vehicle control N= 4; week 1, N= 4; week 2, N= 5 ; 
week 3, N= 5; week 4, N= 5;  week 5, N= 4;) significance is represented as * =P˂0.05, ** =P˂0.01, *** =P˂0.001 and 
**** =P˂0.0001 versus control, one-way ANOVA with Tukey post-hoc test. 
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Fig. 4 Inducible nitric oxide synthase (iNOS) expression and total nitrite (NO2) production is reduced in rat 
aortic smooth muscle cells (ASMCs) from streptozotocin (STZ) treated rats. Western blots of iNOS expression 
in STZ-treated and vehicle control ASMCs treated with IFN-γ and LPS (A). β-actin bands (B). Densitometric 
analysis of iNOS expression in STZ-treated and vehicle control ASMCs (N= 5) (C). Griess assay of total NO2 
released from STZ-treated and vehicle control ASMCs (N= 6) (D). Data are presented as mean ± S.E.M. iNOS 
expression after normalising to beta actin was normalized as percentage of the positive vehicle control iNOS 
expression. Total NO2 was normalized as percentage of the positive vehicle control total NO2 release. Significance 
is represented as * =P˂0.05, ** =P˂0.01 and *** =P˂0.001 by one-way ANOVA with Tukey post-hoc test. 
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Fig. 5 Inhibition of inducible nitric oxide synthase (iNOS) expression and total nitrite (NO2) release in 
ASMCs by methylglyoxal (MGO). Western blots of iNOS expression (A). β-actin bands (B). Densitometric 
analysis of inducible nitric oxide synthase (iNOS) expression with/without interferon-γ (IFN-γ), 
lipopolysaccharide (LPS) treated with MGO (0, 10, 100 µM) and with MGO (100 µM) only (C). Griess assay of 
total NO2 released from ASMCs incubated with/without interferon-γ (IFN-γ), lipopolysaccharide (LPS) treated 
with MGO (0, 10, 100 µM) and with MGO (100 µM) only (D). Data are presented as mean ± S.E.M.; (N= 4). iNOS 
expression after normalising to beta actin was normalized as a percentage of the positive control iNOS 
expression. Total NO2 was normalized as percentage of the positive control total NO2 release. Significance is 
represented as *** =P˂0.001 versus positive control, $ =P˂0.05, $$ =P˂0.01 and $$$ =P˂0.001 versus IFN-γ + LPS + 
MGO (100 µM) for 24 h analyzed by Tukey’s one-way ANOVA. 
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Fig. 6 IFN-γ and LPS stimulation of Akt phosphorylation is blocked by methylglyoxal (MGO) 100 µM. SDS-
PAGE western blotting showing p-Akt expression bands (A). β-actin bands (B). ASMCs were incubated with 
IFN-γ, LPS and MGO 100 µM for 24 h compared to positive control ASMCs were incubated with IFN-γ and LPS 
only (C). Data are presented as mean ± S.E.M.; (N= 3). Phosphorylated Akt (p-Akt) after normalising to beta actin 
was normalized as percentage of the positive control p-Akt expression Significance is represented as * =P˂0.05 
and ** =P˂0.01 by Tukey’s one-way ANOVA. 
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Fig. 7 IFN-γ and LPS do not stimulate p38 phosphorylation. SDS-PAGE western blotting showing p-p38 
expression bands (A). β-actin bands (B). Densitometric analysis of p-p38 expression in ASMCs were incubated 
with IFN-γ, LPS and MGO 100 µM for 24 h compared to ASMCs incubated with IFN-γ and LPS only (N= 3) (C). 
Data are presented as mean ± S.E.M.; (N= 3). Phosphorylated p38 (p-p38) after normalizing to beta actin was 
normalized as percentage of the positive control p-p38 expression, showing non-significant effect P˃0.05 by 
Tukey’s one-way ANOVA. 
  
Accepted version of: Shamsaldeen, Y., Alsugoor, M., Lione, L., & Benham, C. (2019). Dysfunction in nitric oxide synthesis in streptozotocin treated 
rat aorta and role of methylglyoxal. European Journal of Pharmacology, 842, 321-328. [EJP-48005R3]. https://doi.org/10.1016/j.ejphar.2018.10.056 
19 
 
 
Fig. 8. MGO inhibition of IFN-γ and LPS stimulated inducible nitric oxide synthase (iNOS) expression and 
total nitrite (NO2) release is prevented by L-arginine co-incubation. SDS-PAGE Western blot for iNOS 
expression (A). β-actin bands (B). Densitometric analysis of ASMCs inducible nitric oxide synthase (iNOS) 
expression with/without interferon-γ (IFN-γ) and lipopolysaccharide (LPS) with/without methylglyoxal (MGO) 
(100 µM) and L-arginine (100 µM) (C). Griess assay of total NO2 released from ASMCs with/without 
methylglyoxal (MGO) and L-arginine (D). Data are presented as mean ± S.E.M.; (N= 4). iNOS expression after 
normalising to beta actin was normalized as percentage of the positive control iNOS expression. Total NO2 was 
normalized as percentage of the positive control total NO2- release. Significance is represented as ** =P˂0.01 and 
*** =P˂0.001 versus positive control, $$ =P˂0.01 and $$$ =P˂0.001 versus IFN-γ + LPS + MGO 24 h, # =P˂0.05 
versus IFN-γ + LPS + MGO + L-arginine, and ^^ =P˂0.01 and ^^^ =P˂0.001 versus IFN-γ + LPS + L-arginine, when 
analysed by Tukey’s one-way ANOVA. 
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